<DOC>
	<DOCNO>NCT01873495</DOCNO>
	<brief_summary>The purpose pilot study assess safety tolerability omacetaxine consolidation patient age 55 old acute myelogenous leukemia ( AML ) first complete remission follow induction cytarabine anthracycline , also assess safety tolerability omacetaxine maintenance patient age 55 old acute AML first complete remission follow 3 consolidation course omacetaxine .</brief_summary>
	<brief_title>Omacetaxine Consolidation Maintenance</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<criteria>1 . Diagnosis AML include de novo , secondary , antecedent hematologic disorder ( AHD ) accord World Health Organization ( WHO ) criterion . 2 . Age ≥ 55 year . 3 . Patient eligible standard induction chemotherapy base Eastern Cooperative Oncology Group ( ECOG ) performance status vital organ function discretion treat physician . 4 . Patients receive 12 cycle hypomethylating therapy ( decitabine azacitidine ) eligible . 5 . Provide sign write informed consent . 6 . Be able comply study procedure followup examination . 7 . Be nonfertile agree use birth control study end last treatment visit . 8 . Adequate renal hepatic function time second registration : Total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ; Serum creatinine ≤ 1.2 x ULN . 9 . ECOG performance ≤ 2 time second registration . 10 . Patients history carcinoma remission , therapy hormonal therapy adjuvant treatment breast carcinoma prostate carcinoma include study . 1 . Diagnosis acute promyelocytic leukemia ( APL , FrenchAmericanBritish [ FAB ] classification M3 WHO classification APL ( 15 ; 17 ) ( q22 ; q12 ) , ( PML/retinoic acid receptor alpha [ RARa ] variant ) . 2 . Prior treatment omacetaxine . 3 . Relapsed refractory AML . 4 . Investigational agent receive within 30 day prior first dose study drug . If receive investigational agent prior time point , drugrelated toxicity must recover Grade 2 less prior first dose study drug . 5 . Psychiatric disorder would interfere consent , study participation , followup . 6 . Systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . 7 . Any severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo propose therapy . This include uncontrolled hypertension uncontrolled diabetes , case life threaten hyperglycemia report ( use continuous infusion high dos omacetaxine ) . 8 . Active carcinoma require systemic chemotherapy radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>